Member news! Meissa Vaccines enters into cGMP manufacturing agreement with @ExotheraWorld for pediatric RSV vaccine candidate for phase 2 clinical trials. https://t.co/qsXIscnWsE
Exothera Viral Vectors will manufacture Meissa Vaccines’s MV-012-968 vaccine candidate, an intranasal live attenuated RSV aiming to protect infants and young children from respiratory syncytial virus (RSV). Read the Press Release: https://t.co/Stam5VBcIJ
As Chief Technology Officer, Patrick Thiaville will help to accelerate the delivery of high-quality development and manufacturing services for the next generation of RNA therapies! 👏👍 Read the Press Release: https://t.co/7iTcdrFFUD
@ExotheraWorld announces a strategic partnership with Quantoom Biosciences and launches a new business unit for the development and production of RNA #RNAproduction#CDMO
https://t.co/fjjcD9x7i5
[PRESS RELEASE] Exothera Nucleic Acids will be the world’s first CDMO with access to Quantoom Biosciences’s revolutionary Nfinity™ platform for the continuous production of RNA which Exothera will offer as a service! Discover the press release: https://t.co/LEZmOgQzFH
[PRESS RELEASE]
We are thrilled to announce this new collaboration in which Exothera will demonstrate the industrialization potential of @RemediumB's AAV-based gene therapy for the treatment of Osteoarthritis! Click here to discover the press release: https://t.co/DrtKVnFo6Z
We are thrilled to welcome Darren Leva as our new Chief Business Officer. With his extensive experience in the biotech industry and a proven track record of driving growth, he is the perfect addition to our team. 😀👍 READ THE PRESS RELEASE: https://t.co/tMSVnIxyUt
We’re delighted to announce @ExotheraWorld will be developing a large-scale manufacturing process for the clinical development of VALO-D102, our proprietary oncolytic adenovirus which forms part of our PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) platform.
[PRESS RELEASE]
This collaboration among @EXOTHERA, LogicBio Therapeutics, and @Polyplus_Transf aims to develop a highly scalable and cost-effective AAV manufacturing platform! Read the press release: https://t.co/FG3JZuND59
#GeneTherapy#vaccines#AAVManufacturing
[PRESS RELEASE]
This fully integrated platform will ensure faster, more cost-effective production of viral vector-based therapeutics (for gene therapy, vaccines, and oncolytic viruses for cancer treatment) at scale!
► READ THE PRESS RELEASE: https://t.co/X7H2f1xmb7
[PRESS RELEASE] This collaboration will be financed by a €3 million grant awarded by the Bill & Melinda Gates Foundation to develop and deliver new low-cost vaccines based on ReiThera’s GRAd technology platform. Read the Press Release: https://t.co/dbPzYLVLmJ
🗣️ @montsedabanm, Scientific and International Relations Director at #Biocat, has participated today as a panelist at the session "Perspectives on the pan-European manufacturing landscape" together with Jerôme Fabiano from @EIThealth_FR & Thibault Jonckheere from @ExotheraWorld.
Plongeon dans l’univers des #biotechs au travers de 3 filiales d’@UniverCell's, entreprise mondiale des sciences de la vie implantée en #Wallonie et dont l’objectif est d’élargir l’accès aux médicaments biologiques & les rendre plus abordables 💊
#Quantoom@ExotheraWorld
[PRESS RELEASE]
Rokote Laboratories and Exothera will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials! Read the press release: https://t.co/fQdSY1rTle
#GMPManufacturing#ViralVaccines#GeneTherapy